Absence of Synergism Between a Dual-AMP Biogel and Antibiotics Used As Therapeutic Agents for Diabetic Foot Infections

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jan 11

PMID 38203579

Authors

Rui Silva Soares

Diana Gomes

Isa Serrano

Eva Cunha

Luis Tavares

Manuela Oliveira

Affiliations

Soon will be listed here.

Abstract

Diabetic foot infections (DFIs) are frequently linked to diabetic-related morbidity and death because of the ineffectiveness of conventional antibiotics against multidrug-resistant bacteria. Pexiganan and nisin A are antimicrobial peptides (AMPs), and their application may complement conventional antibiotics in DFI treatment. A collagen 3D model, previously established to mimic a soft-tissue collagen matrix, was used to evaluate the antibacterial efficacy of a guar gum gel containing pexiganan and nisin alone and combined with three antimicrobials toward the biofilms of and isolated from infected foot ulcers. Antimicrobials and bacterial diffusion were confirmed by spot-on-lawn and bacterial growth by bacterial count (cfu/mL). Our main conclusion was that the dual-AMP biogel combined with gentamicin, clindamycin, or vancomycin was not able to significantly reduce bacterial growth or eradicate and DFI isolates. We further reported an antagonism between dual-AMP and dual-AMP combined with antibiotics against .

References

Kohanski M, Dwyer D, Collins J . How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010; 8(6):423-35. PMC: 2896384. DOI: 10.1038/nrmicro2333. View

Dosler S, Mataraci E . In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. Peptides. 2013; 49:53-8. DOI: 10.1016/j.peptides.2013.08.008. View

Price B, Lovering A, Bowling F, Dobson C . Development of a Novel Collagen Wound Model To Simulate the Activity and Distribution of Antimicrobials in Soft Tissue during Diabetic Foot Infection. Antimicrob Agents Chemother. 2016; 60(11):6880-6889. PMC: 5075099. DOI: 10.1128/AAC.01064-16. View

Gottler L, Ramamoorthy A . Structure, membrane orientation, mechanism, and function of pexiganan--a highly potent antimicrobial peptide designed from magainin. Biochim Biophys Acta. 2008; 1788(8):1680-6. PMC: 2726618. DOI: 10.1016/j.bbamem.2008.10.009. View

Wilson D . Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol. 2013; 12(1):35-48. DOI: 10.1038/nrmicro3155. View

Field D, O Connor R, Cotter P, Ross R, Hill C . In Vitro Activities of Nisin and Nisin Derivatives Alone and In Combination with Antibiotics against Staphylococcus Biofilms. Front Microbiol. 2016; 7:508. PMC: 4834297. DOI: 10.3389/fmicb.2016.00508. View

Gomes D, Santos R, S Soares R, Reis S, Carvalho S, Rego P . Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections. Antibiotics (Basel). 2020; 9(3). PMC: 7148459. DOI: 10.3390/antibiotics9030128. View

Cotter P, Ross R, Hill C . Bacteriocins - a viable alternative to antibiotics?. Nat Rev Microbiol. 2012; 11(2):95-105. DOI: 10.1038/nrmicro2937. View

Ferreyra Maillard A, Espeche J, Maturana P, Cutro A, Hollmann A . Zeta potential beyond materials science: Applications to bacterial systems and to the development of novel antimicrobials. Biochim Biophys Acta Biomembr. 2021; 1863(6):183597. DOI: 10.1016/j.bbamem.2021.183597. View

10.

Chen H, Jia P, Kang H, Zhang H, Liu Y, Yang P . Upregulating Hif-1α by Hydrogel Nanofibrous Scaffolds for Rapidly Recruiting Angiogenesis Relative Cells in Diabetic Wound. Adv Healthc Mater. 2016; 5(8):907-18. DOI: 10.1002/adhm.201501018. View

11.

Batoni G, Maisetta G, Esin S . Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim Biophys Acta. 2015; 1858(5):1044-60. DOI: 10.1016/j.bbamem.2015.10.013. View

12.

Senneville E, Albalawi Z, van Asten S, Abbas Z, Allison G, Aragon-Sanchez J . IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clin Infect Dis. 2023; . DOI: 10.1093/cid/ciad527. View

13.

Lipsky B, Berendt A, Cornia P, Pile J, Peters E, Armstrong D . 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012; 54(12):e132-73. DOI: 10.1093/cid/cis346. View

14.

Armstrong D, Boulton A, Bus S . Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017; 376(24):2367-2375. DOI: 10.1056/NEJMra1615439. View

15.

Lipsky B . Diabetic foot infections: Current treatment and delaying the 'post-antibiotic era'. Diabetes Metab Res Rev. 2015; 32 Suppl 1:246-53. DOI: 10.1002/dmrr.2739. View

16.

Santos R, Gomes D, Macedo H, Barros D, Tiberio C, Veiga A . Guar gum as a new antimicrobial peptide delivery system against diabetic foot ulcers Staphylococcus aureus isolates. J Med Microbiol. 2016; 65(10):1092-1099. DOI: 10.1099/jmm.0.000329. View

17.

Lipsky B, Holroyd K, Zasloff M . Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis. 2008; 47(12):1537-45. DOI: 10.1086/593185. View

18.

Mendes J, Marques-Costa A, Vilela C, Neves J, Candeias N, Cavaco-Silva P . Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res Clin Pract. 2011; 95(1):153-61. DOI: 10.1016/j.diabres.2011.10.001. View

19.

Park S, Park Y, Hahm K . The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int J Mol Sci. 2011; 12(9):5971-92. PMC: 3189763. DOI: 10.3390/ijms12095971. View

20.

Werthen M, Henriksson L, Jensen P, Sternberg C, Givskov M, Bjarnsholt T . An in vitro model of bacterial infections in wounds and other soft tissues. APMIS. 2010; 118(2):156-64. DOI: 10.1111/j.1600-0463.2009.02580.x. View